Comparison of Efficacy of Neovasculgen® and Botox® in the treating Interstitial Cystitis/Bladder Pain Syndrome: experimental study

Introduction. Interstitial cystitis/bladder pain syndrome (IC/BPS), being a chronic non-infectious disease, still has an unclear etiology and numerous pathophysiological theories of development. This determines the need for preclinical experimental studies on animals. The most identical model of human IC/BPS is cyclophosphamide-induced cystitis in rodents. Objective. To study the effects of the pharmacological activity of Neovasculgen® сompared to Botox® using model of cyclophosphamide-induced IC/BPS in rats. Materials & methods. The study was performed on 90 female Wistar rats. IC/BPS was induced by Endoxan®. Neovasculgen® and Botox® were used as intradetrusor therapeutic agents. Efficiency was assessed by comparative analysis of urodynamic patterns and morphologically. The data obtained were processed by parametric and nonparametric methods of statistical analysis. Results. Cyclophosphamide-induced IC/BPS developed in all animals. Both drugs statistically significantly improved the studied urodynamic parameters, the clinical efficacy of Neovasculgen® was comparable to Botox®. Morphological assessment showed that the administration of the studied drugs was accompanied by a decrease in tissue edema, less pronounced hemorrhages and focal lymphohistiocytic infiltration, as well as destructive changes in the bladder mucosa. At the same time, the intensity of pathological tissue processes against the background of the administration of Neovasculgen® was the lowest. Conclusions. The cyclophosphamide-induced IC/BPS model is considered the most adequate human IC/BPS. The experiment is extremely important for studying the effectiveness of a new drug, which is intradetrusor Neovasculgen®. The drug has shown its effectiveness in reducing the frequency of urination and intravesical pressure. Intradetrusor administration reduces the severity of the inflammatory reaction of bladder tissue.